Display options
Cite
Horikawa Y, Enya M, Iizuka K, et al. Synergistic effect of α-glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment. J Diabetes Investig. 2011;2(3):200-3doi: 10.1111/j.2040-1124.2010.00081.x.
Horikawa, Y., Enya, M., Iizuka, K., Chen, G. Y., Kawachi, S., Suwa, T., & Takeda, J. (2011). Synergistic effect of α-glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment. Journal of diabetes investigation, 2(3), 200-3. https://doi.org/10.1111/j.2040-1124.2010.00081.x
Horikawa, Yukio, et al. "Synergistic effect of α-glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment." Journal of diabetes investigation vol. 2,3 (2011): 200-3. doi: https://doi.org/10.1111/j.2040-1124.2010.00081.x
Horikawa Y, Enya M, Iizuka K, Chen GY, Kawachi S, Suwa T, Takeda J. Synergistic effect of α-glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment. J Diabetes Investig. 2011 Jun 05;2(3):200-3. doi: 10.1111/j.2040-1124.2010.00081.x. PMID: 24843484; PMCID: PMC4014919.
Copy Download .nbib Format: NLM
Share it on

J Diabetes Investig. 2011 Jun 05;2(3):200-3. doi: 10.1111/j.2040-1124.2010.00081.x.

Synergistic effect of α-glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment.

Journal of diabetes investigation

Yukio Horikawa, Mayumi Enya, Katsumi Iizuka, Gui Ying Chen, Shin-Ichi Kawachi, Tetsuya Suwa, Jun Takeda

Affiliations

  1. Department of Diabetes and Endocrinology, Graduate School of Medicine, Gifu University, Gifu, Japan.

PMID: 24843484 PMCID: PMC4014919 DOI: 10.1111/j.2040-1124.2010.00081.x

Abstract

Monotherapy of α-glucosidase inhibitor (α-GI) or dipeptidyl peptidase 4 (DPP4) inhibitor does not sufficiently minimize glucose fluctuations in the diabetic state. In the present study, we evaluated the combined effects of various of α-GI inhibitors (acarbose, voglibose or miglitol) and sitagliptin, a DPP4 inhibitor, on blood glucose fluctuation, insulin and active glucagon-like peptide-1 (GLP-1) levels after nutriment loading in mice. Miglitol and sitagliptin elicited a 47% reduction (P < 0.05) of the area under the curve of blood glucose levels for up to 2 h after maltose-loading, a 60% reduction (P < 0.05) in the range of blood glucose fluctuation, and a 32% decrease in plasma insulin compared with the control group. All three of the combinations elicited a 2.5-4.9-fold synergistic increase in active GLP-1 (P < 0.05 vs control). Thus, combined treatment with the α-GI miglitol, which more strongly inhibits the early phase of postprandial hyperglycemia, and DPP4 inhibitor yields both complementary and synergistic effects, and might represent a superior anti-hyperglycemic therapy. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2010.00081.x, 2011).

Keywords: Glucagon‐like peptide‐1; Insulin; Postprandial hyperglycemia

References

  1. Circulation. 2002 Dec 3;106(23):2908-12 - PubMed
  2. Lancet. 2002 Jun 15;359(9323):2072-7 - PubMed
  3. Eur J Pharmacol. 2009 Dec 10;624(1-3):51-7 - PubMed
  4. J Clin Endocrinol Metab. 2008 Apr;93(4):1345-50 - PubMed
  5. Biochem Biophys Res Commun. 2007 Jul 6;358(3):679-85 - PubMed
  6. Diabetes. 2010 Apr;59(4):1030-7 - PubMed
  7. Diabetes Obes Metab. 2002 Sep;4(5):329-35 - PubMed
  8. Cell Metab. 2006 Mar;3(3):153-65 - PubMed
  9. J Pharmacol Sci. 2007 May;104(1):29-38 - PubMed
  10. Lancet. 2010 Jan 9;375(9709):132-40 - PubMed
  11. Scand J Gastroenterol. 1995 Sep;30(9):892-6 - PubMed
  12. Diabet Med. 2009 Feb;26(2):187-8 - PubMed
  13. Diabetes Obes Metab. 2010 Mar;12(3):224-33 - PubMed

Publication Types